Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Louis Bucky

Plastic and Reconstructive Surgery Ardmore, PA Medical Doctor

NPI 1609808757 CMS profile 253835

200 W Montgomery Ave, Ardmore, PA 19003

Open in the dashboard

General payments

$86,961

147 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Louis Bucky of Ardmore, PA is reported in the CMS Open Payments database as having received $86,961 across 147 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $547 13
2024 General $534 15
2023 General $1,975 9
2022 General $880 15
2021 General $2,691 18
2020 General $31,497 9
2019 General $48,838 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Louis Bucky
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Louis Bucky were reported at $547. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Louis Bucky Plastic and Reconstructive Surgery median Middle half National median
2019 $48,838 $335 $121–$1,264 $163
2020 $31,497 $162 $57–$417 $114
2021 $2,691 $245 $89–$735 $132
2022 $880 $325 $120–$932 $149
2023 $1,975 $343 $129–$999 $160
2024 $534 $390 $141–$1,085 $164
2025 $547 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $80,801 95 payments
  2. AbbVie, Inc. $2,542 22 payments
  3. Galderma Laboratories, L.P. $2,199 7 payments
  4. Merz North America, Inc. $863 8 payments
  5. Revance Therapeutics, Inc. $223 7 payments
  6. Davol Inc. $116 3 payments
  7. TELA Bio, Inc. $115 2 payments
  8. Bard Peripheral Vascular, Inc. $66 2 payments
  9. Boston Scientific Corporation $37 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $69,110 10 payments
  2. Gift $12,208 6 payments
  3. Food and Beverage $5,643 131 payments
Products named General payments · program years 2019–2025
  1. BOTOX COSMETIC $41,487 25 payments
  2. ALLODERM $22,581 5 payments
  3. NATRELLE $13,242 23 payments
  4. BOTOX $2,426 9 payments
  5. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $2,135 12 payments
  6. Xeomin $700 6 payments
  7. ASCLERA $664 4 payments
  8. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $585 10 payments
  9. DAXXIFY $223 7 payments
  10. OviTex 2S $77 1 payment
  11. Other $192 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

290

Median for General Surgery: 59

Drug cost

$1,956

Median for General Surgery: $393

Branded share of claims

47.9%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Valacyclovir Valacyclovir Hcl Brand 56 $515
Cefadroxil Generic 61 $411
Scopolamine Generic 26 $323
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 33 $257
Ondansetron Odt Ondansetron Brand 50 $207
Montelukast Sodium Generic 24 $118
Diazepam Generic 26 $105
Alprazolam Generic 14 $19

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $91
$91 — —
DYSPORT
  • Galderma Laboratories, L.P. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

147 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record